Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis.
When do infants and young children with cystic fibrosis acquire infection with Pseudomonas aeruginosa? Can this be eradicated when first detected? Children <6 yrs of age participated in an annual bronchoalveolar lavage (BAL)-based microbiological surveillance programme in Perth, Australia. When P. aeruginosa was detected, an eradication programme using combination treatment with i.v., oral and nebulised antibiotics was undertaken. Repeat BAL was performed 3 months following treatment, to assess eradication success. P. aeruginosa was detected in 33 (28.4%) children; median (range) age at detection was 30.5 (3.3-71.4) months. P. aeruginosa was mucoid at detection in six (18.2%) out of 33 patients and associated with respiratory symptoms in 16 (48.5%) out of 33 children. In total, 26 children underwent eradication therapy, with P. aeruginosa eradicated in 20 (77%) out of 26 following one eradication cycle and in three (total 88%) additional children following a second cycle. Eradication was associated with a significant decrease in neutrophil elastase and interleukin-1beta in BAL fluid 12 months post eradication. Eradication of Pseudomonas aeruginosa infection is achievable in young children with cystic fibrosis for up to 5 yrs using combination i.v., oral and nebulised antibiotic therapy and is associated with reduced pulmonary inflammation 12 months post eradication.
Douglas
T A
TA
Telethon Institute for Child Health Research, Centre for Child Health Research, University of Western Australia Perth, Western Australia.
Brennan
S
S
Gard
S
S
Berry
L
L
Gangell
C
C
Stick
S M
SM
Clements
B S
BS
Sly
P D
PD
D000284:Administration, Oral; D001992:Bronchoalveolar Lavage Fluid; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000150:complications* / Q000188:drug therapy* / Q000453:epidemiology; D005260:Female; D006801:Humans; D007223:Infant; D007249:Inflammation; D053583:Interleukin-1beta / Q000378:metabolism; D019272:Leukocyte Elastase / Q000378:metabolism; D008168:Lung / Q000382:microbiology / Q000473:pathology; D008297:Male; D011552:Pseudomonas Infections / Q000150:complications* / Q000188:drug therapy* / Q000453:epidemiology; D011550:Pseudomonas aeruginosa / Q000378:metabolism; D013997:Time Factors
D053583:Interleukin-1beta; D019272:Leukocyte Elastase